In vitro and in vivo evaluation of the effects of aluminum [18F]fluoride radiolabeling on an integrin αvβ6-specific peptide

Nuclear Medicine and Biology

Volumn 41, Issue 1, 2014, Pages 43-50

  Hausner, Sven H ^a,b   Bauer, Nadine ^a   Sutcliffe, Julie L ^a,b  

^a University of California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aluminum 18F fluoride; Fluorine 18; Integrin; NOTA; Peptide; Positron emission tomography

Indexed keywords

ACETIC ACID; ALPHAVBETA6 INTEGRIN; FLUORINE ALUMINUM 2 [4,7 BIS(2 (TERT BUTOXY) 2 OXOETHYL] 1,4,7 TRIAZONAN 1 YL)ACETIC ACID PEG28 A20FMDV2 F 18; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL ADHESION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG BINDING; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TUMOR LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; MOLECULAR IMAGING; MOUSE; NONHUMAN; PH MEASUREMENT; RADIOACTIVITY; RADIOCHEMISTRY;

ALUMINUM [18F]FLUORIDE; FLUORINE 18; INTEGRIN; NOTA; PEPTIDE; POSITRON EMISSION TOMOGRAPHY;

ALUMINUM; ANIMALS; ANTIGENS, NEOPLASM; BENZOATES; CELL LINE, TUMOR; DRUG STABILITY; FEMALE; FLUORINE RADIOISOTOPES; HETEROCYCLIC COMPOUNDS; INTEGRINS; ISOTOPE LABELING; MICE; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; SUBSTRATE SPECIFICITY;

EID: 84888338977     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.09.009     Document Type: Article

References (32)

1. McBride W.J., Sharkey R.M., Goldenberg D.M. Radiofluorination using aluminum-fluoride (Al18F). EJNMMI Res 2013, 3:36.
2. Dijkgraaf I., Franssen G.M., McBride W.J., D'Souza C.A., Laverman P., Smith C.J., et al. PET of tumors expressing gastrin-releasing peptide receptor with an F-18-labeled bombesin analog. J Nucl Med 2012, 53:947-952.
3. McBride W.J., D'Souza C.A., Sharkey R.M., Karacay H., Rossi E.A., Chang C.H., et al. Improved F-18 labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjugate Chem 2010, 21:1331-1340.
4. Wan W.X., Guo N., Pan D.H., Yu C.J., Weng Y., Luo S.N., et al. First experience of F-18-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med 2013, 54:691-698.
5. Bandyopadhyay A., Raghavan S. Defining the role of integrin alpha v beta 6 in cancer. Curr Drug Targets 2009, 10:645-652.
6. Impola U., Uitto V.J., Hietanen J., Hakkinen L., Zhang L., Larjava H., et al. Differential expression of matrilysin-1 (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer. J Pathol 2004, 202:14-22.
7. Saha A., Ellison D., Thomas G.J., Vallath S., Mather S.J., Hart I.R., et al. High-resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin alpha v beta 6. J Pathol 2010, 222:52-63.
8. Arihiro K., Kaneko M., Fujii S., Inai K., Yokosaki Y. Significance of alpha 9 beta 1 and alpha v beta 6 integrin expression in breast carcinoma. Breast Cancer 2000, 7:19-26.
9. Ahmed N., Riley C., Rice G.E., Quinn M.A., Baker M.S. Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer. J Histochem Cytochem 2002, 50:1371-1380.
10. Hazelbag S., Kenter G.G., Gorter A., Dreef E.J., Koopman L.A., Violette S.M., et al. Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J Pathol 2007, 212:316-324.
11. Elayadi A.N., Samli K.N., Prudkin L., Liu Y.H., Bian A.H., Xie X.J., et al. A peptide selected by biopanning identifies the integrin alpha(v)beta(6) as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res 2007, 67:5889-5895.
12. Bates R.C. Colorectal cancer progression - integrin alpha v beta 6 and the epithelial-mesenchymal transition (EMT). Cell Cycle 2005, 4:1350-1352.
13. Zhang Z.Y., Xu K.S., Wang J.S., Yang G.Y., Wang W., Wang J.Y., et al. Integrin alpha v beta 6 acts as a prognostic indicator in gastric carcinoma. Clin Oncol 2008, 20:61-66.
14. Hausner S.H., Abbey C.K., Bold R.J., Gagnon M.K., Marik J., Marshall J.F., et al. Targeted in vivo imaging of integrin alpha(v)beta(6) with an improved radiotracer and its relevance in a pancreatic tumor model. Cancer Res 2009, 69:5843-5850.
15. Hausner S.H., Marik J., Gagnon M.K.J., Sutcliffe J.L. In vivo positron emission tomography (PET) imaging with an alpha(v)beta(6) specific peptide radiolabeled using F-18-"click" chemistry: Evaluation and comparison with the corresponding 4-[F-18]fluorobenzoyl- and 2-[F-18]fluoropropionyl-peptides. J Med Chem 2008, 51:5901-5904.
16. Hausner S.H., DiCara D., Marik J., Marshall J.F., Sutcliffe J.L. Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: Generation and evaluation of 4-[F-18]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alpha(v)beta(6) expression with positron emission tomography. Cancer Res 2007, 67:7833-7840.
17. Hancock W.S., Battersby J.E. New micro-test for detection of incomplete coupling reactions in solid-phase peptide-synthesis using 2,4,6-trinitrobenzene-sulphonic acid. Anal Biochem 1976, 71:260-264.
18. Reilly R.M., Kiarash R., Cameron R.G., Porlier N., Sandhu J., Hill R.P., et al. In-111-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med 2000, 41:429-438.
19. Gottumukkala V., Heinrich T.K., Baker A., Dunning P., Fahey F.H., Treves S.T., et al. Biodistribution and stability studies of [F-18]Fluoroethylrhodamine B, a potential PET myocardial perfusion agent. Nucl Med Biol 2010, 37:365-370.
20. Ametamey S.M., Honer M., Schubiger P.A. Molecular imaging with PET. Chem Rev 2008, 108:1501-1516.
21. Miller P.W., Long N.J., Vilar R., Gee A.D. Synthesis of C-11, F-18, O-15, and N-13 radiolabels for positron emission tomography. Angew Chem Int Ed 2008, 47:8998-9033.
22. Lee S., Xie J., Chen X. Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev 2010, 110:3087-3111.
23. Tang G.H., Tang X.L., Wang X.L. A facile automated synthesis of N-succinimidyl 4-[F-18]fluorobenzoate ([F-18]SFB) for F-18-labeled cell-penetrating peptide as PET tracer. J Labelled Compd Radiopharm 2010, 53:543-547.
24. Wadas T.J., Wong E.H., Weisman G.R., Anderson C.J. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev 2010, 110:2858-2902.
25. Hausner S.H., Kukis D.L., Gagnon M.K.J., Stanecki C.E., Ferdani R., Marshall J.F., et al. Evaluation of [Cu-64]Cu-DOTA and [Cu-64]Cu-CB-TE2A chelates for targeted positron emission tomography with an alpha(v)beta(6)-specific peptide. Mol Imaging 2009, 8:111-121.
26. D'Souza C.A., McBride W.J., Sharkey R.M., Todaro L.J., Goldenberg D.M. High-yielding aqueous 18F-labeling of peptides via Al18F chelation. Bioconjug Chem 2011, 22:1793-1803.
27. Smith G.E., Sladen H.L., Biagini S.C., Blower P.J. Inorganic approaches for radiolabelling biomolecules with fluorine-18 for imaging with positron emission tomography. Dalton Trans 2011, 40:6196-6205.
28. Marsh D., Dickinson S., Neill G.W., Marshall J.F., Hart I.R., Thomas G.J. alpha v beta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation. Cancer Res 2008, 68:3295-3303.
29. Van Aarsen L.A., Leone D.R., Ho S., Dolinski B.M., McCoon P.E., LePage D.J., et al. Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res 2008, 68:561-570.
30. Akizawa H., Uehara T., Arano Y. Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins. Adv Drug Deliv Rev 2008, 60:1319-1328.
31. Kiesewetter D.O., Guo N., Guo J., Gao H., Zhu L., Ma Y., et al. Evaluation of an [F-18]AlF-NOTA analog of exendin-4 for imaging of GLP-1 receptor in insulinoma. Theranostics 2012, 2:999-1009.
32. Heskamp S., Laverman P., Rosik D., Boschetti F., van der Graaf W.T., Oyen W.J., et al. Imaging of human epidermal growth factor receptor type 2 expression with [F-18]labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer. J Nucl Med 2012, 53:146-153.